Tersigni R, Alessandroni L, Baiano G, Mencacci R, Miceli M, Sadighi A, Sorgi G, Tremiterra S
Struttura Complessa di Chirurgia Generale 1 Flajani, Azienda Ospedaliera, San Camillo-Forlanini, Rome.
Minerva Chir. 2004 Oct;59(5):479-87.
Surgery is, at present, the only potentially curative treatment for gastric carcinoma. The curability depends upon the extension and localization of the tumor and, particularly, the lymphatic involvement and the presence of distant metastases. The aim of this paper is to describe the personal experience during the last 2 decades and analyze the results of the surgical approach which has changed over the time.
One-hundred and ninety-four consecutive patients have been reported (127 male and 67 female, with a median age of 65.8 years), affected by gastric carcinoma and subjected to surgical procedures from 1987 to 2000. Because of the wide period of time which it refers to, this study is overlapped by a radical change in the staging rules of gastric carcinoma, according to the publication, in 1997, of the 5th edition of the TNM. This has made necessary to divide the series into 2 different groups. The 1st group is composed of 123 patients (63.4%), staged according to TNM-1987; the 2(nd) group is composed of 71 patients (36.6%) staged according to the TNM-1997. A D1 lymphadenectomy was used as treatment protocol until 1995. Subsequently, a D2 lymphadenectomy was performed in the most part of potentially curable patients. The reconstruction after total gastrectomy was carried out in all cases with Roux technique. In distal gastrectomies a Billroth 2 technique was performed in 89.3% of the cases and a Billroth 1 technique in 10.7% of the cases.
The operative mortality observed on the total of patients was 1.5% (3 cases). With a median follow-up of 83 months (minimal 24, maximum 180 months), 134 patients were died, 50 are alive and 10 have been lost. The total median survival, in the 2 groups, was 24 months. We have observed a trend to improvement of survival for patients with carcinoma in stage II and III operated after 1997.
The treatment of unresectable gastric cancer, i.e. palliative surgery, is the best choice when possible in comparison to other surgical procedures (gastroenteronastomosis, jejunostomy), endoscopic procedures (dilatation, endoprosthesis, laser, percutaneous endoscopic gastrostomy) and medical therapies. In order to choose the best palliative treatment, a careful evaluation of the non-curability signs is necessary to avoid high risk surgical interventions in patients with a low expectation of life.
目前,手术是胃癌唯一可能治愈的治疗方法。治愈率取决于肿瘤的扩展和定位,特别是淋巴受累情况及远处转移的存在。本文旨在描述过去20年的个人经验,并分析随着时间推移手术方法的结果变化。
报告了194例连续患者(男性127例,女性67例,中位年龄65.8岁),他们在1987年至2000年期间患有胃癌并接受了手术治疗。由于所涉及的时间跨度较大,根据1997年第5版TNM的发表,本研究因胃癌分期规则的根本性变化而有所重叠。这使得有必要将该系列分为2个不同的组。第一组由123例患者(63.4%)组成,根据TNM - 1987分期;第二组由71例患者(36.6%)组成,根据TNM - 1997分期。直到1995年,D1淋巴结清扫术被用作治疗方案。随后,在大多数可能治愈的患者中进行了D2淋巴结清扫术。全胃切除术后的重建在所有病例中均采用Roux技术。在远端胃切除术中,89.3%的病例采用毕罗Ⅱ式技术,10.7%的病例采用毕罗Ⅰ式技术。
观察到患者的总手术死亡率为1.5%(3例)。中位随访83个月(最短24个月,最长180个月),134例患者死亡,50例存活,10例失访。两组的总中位生存期为24个月。我们观察到1997年后接受手术的Ⅱ期和Ⅲ期癌症患者的生存有改善趋势。
与其他手术程序(胃肠吻合术、空肠造口术)、内镜程序(扩张、内置假体、激光、经皮内镜胃造口术)和药物治疗相比,不可切除胃癌的治疗,即姑息性手术,在可能的情况下是最佳选择。为了选择最佳的姑息治疗方法,有必要仔细评估不可治愈的体征,以避免对预期寿命较低的患者进行高风险的手术干预。